This document provides an overview of pharmacodynamics and molecular targets for drugs. It discusses how drugs act by interacting with receptors, including ligand-gated ion channels and G-protein coupled receptors. Examples of molecular targets are given such as enzymes, transporters, ion channels, and receptor types. The concepts of agonism, antagonism, and partial agonism in relation to drug-receptor binding and activation of receptor conformational states are also summarized.
Receptor types, mechanism, receptor pharmacology, drug receptor interactions, theories of receptor pharmacology, spare receptors and new concepts like biased agonism
This document discusses stereochemistry and its importance in drug action. It defines key terms like chirality, enantiomers, and diastereomers. Many drugs are chiral and exist as two non-superimposable mirror images. The document provides examples of chiral drugs like adrenaline, local anesthetics, inhalational agents, and neuromuscular blocking agents. It discusses how the two enantiomers of a drug can have different pharmacological effects and toxicity profiles. The absorption, distribution, metabolism, and excretion of drug enantiomers may also differ due to stereoselectivity at various biological levels.
This document discusses pharmacodynamics and receptor interactions. It defines pharmacodynamics as the relationship between drug concentration at the receptor site and the resulting pharmacological response. It describes the four main receptor families - ligand-gated ion channels, G protein-coupled receptors, enzyme-linked receptors, and intracellular receptors. It also discusses receptor ligands, agonists, antagonists, affinity, efficacy, dose-response relationships, and therapeutic indices.
The document provides an overview of pharmacodynamics, which is how drugs act on the body. It discusses drug receptor interactions including agonists that activate receptors, antagonists that block receptors, and partial agonists that partially activate receptors. It also covers non-receptor mechanisms of drug action such as effects on enzymes. The time and dose responses of drugs are described, as well as factors affecting drug activity like absorption, distribution, metabolism and excretion.
1. The document discusses drug receptor interaction theories including occupation theory, rate theory, induced fit theory, macromolecular perturbation theory, activation-aggregation theory, and two-state receptor model.
2. It classifies ligands that bind to receptors as full agonists, partial agonists, or antagonists and describes different types of agonists and antagonists.
3. The key forces involved in drug-receptor binding are described as well as interactions that stabilize drug-receptor complexes such as ionic interactions, hydrogen bonding, and hydrophobic interactions.
This presentation discusses drug antagonism and neurotransmitters. It defines drug antagonism as one drug inhibiting the action of another drug, describing four types: physical, chemical, physiological/functional, and pharmacological antagonism. It then focuses on pharmacological antagonism, distinguishing between competitive and non-competitive receptor antagonism. The presentation also defines neurotransmitters as chemical signals released at synapses that activate receptors and transmit electrical signals between neurons. It classifies and describes several major neurotransmitters, including amino acids, monoamines, acetylcholine, and their functions in the brain and body. References used in creating the presentation are also listed.
Ch02 Drug Receptor Interactions And Pharmacodynamicsaxix
This document summarizes key concepts about drug-receptor interactions and pharmacodynamics from Chapter 2. It discusses how drugs produce effects by binding to receptors on cells and tissues. It defines terms like agonists, antagonists, affinity, efficacy and potency. It also describes different types of receptors that drugs can bind to, including G-protein coupled receptors and intracellular receptors. Finally, it explains the concepts of spare receptors, desensitization, and the different types of antagonism - competitive and noncompetitive.
Pharmacodynamics By Dr Debasish Pradhangundu333pappu
This document discusses pharmacodynamics and the mechanisms of drug action. It describes how drugs can act through physical/chemical properties, stimulation, depression, irritation, replacement or cytotoxic effects. However, most drugs act by interacting with biomolecules like enzymes, ion channels, transporters or receptors. The four main types of receptor-mediated drug actions are agonism, antagonism, partial agonism, and inverse agonism. Downstream effects are mediated through four major transduction pathways: G-protein coupled receptors, receptors with intrinsic ion channels, enzyme-linked receptors, and transcription factors.
Receptor types, mechanism, receptor pharmacology, drug receptor interactions, theories of receptor pharmacology, spare receptors and new concepts like biased agonism
This document discusses stereochemistry and its importance in drug action. It defines key terms like chirality, enantiomers, and diastereomers. Many drugs are chiral and exist as two non-superimposable mirror images. The document provides examples of chiral drugs like adrenaline, local anesthetics, inhalational agents, and neuromuscular blocking agents. It discusses how the two enantiomers of a drug can have different pharmacological effects and toxicity profiles. The absorption, distribution, metabolism, and excretion of drug enantiomers may also differ due to stereoselectivity at various biological levels.
This document discusses pharmacodynamics and receptor interactions. It defines pharmacodynamics as the relationship between drug concentration at the receptor site and the resulting pharmacological response. It describes the four main receptor families - ligand-gated ion channels, G protein-coupled receptors, enzyme-linked receptors, and intracellular receptors. It also discusses receptor ligands, agonists, antagonists, affinity, efficacy, dose-response relationships, and therapeutic indices.
The document provides an overview of pharmacodynamics, which is how drugs act on the body. It discusses drug receptor interactions including agonists that activate receptors, antagonists that block receptors, and partial agonists that partially activate receptors. It also covers non-receptor mechanisms of drug action such as effects on enzymes. The time and dose responses of drugs are described, as well as factors affecting drug activity like absorption, distribution, metabolism and excretion.
1. The document discusses drug receptor interaction theories including occupation theory, rate theory, induced fit theory, macromolecular perturbation theory, activation-aggregation theory, and two-state receptor model.
2. It classifies ligands that bind to receptors as full agonists, partial agonists, or antagonists and describes different types of agonists and antagonists.
3. The key forces involved in drug-receptor binding are described as well as interactions that stabilize drug-receptor complexes such as ionic interactions, hydrogen bonding, and hydrophobic interactions.
This presentation discusses drug antagonism and neurotransmitters. It defines drug antagonism as one drug inhibiting the action of another drug, describing four types: physical, chemical, physiological/functional, and pharmacological antagonism. It then focuses on pharmacological antagonism, distinguishing between competitive and non-competitive receptor antagonism. The presentation also defines neurotransmitters as chemical signals released at synapses that activate receptors and transmit electrical signals between neurons. It classifies and describes several major neurotransmitters, including amino acids, monoamines, acetylcholine, and their functions in the brain and body. References used in creating the presentation are also listed.
Ch02 Drug Receptor Interactions And Pharmacodynamicsaxix
This document summarizes key concepts about drug-receptor interactions and pharmacodynamics from Chapter 2. It discusses how drugs produce effects by binding to receptors on cells and tissues. It defines terms like agonists, antagonists, affinity, efficacy and potency. It also describes different types of receptors that drugs can bind to, including G-protein coupled receptors and intracellular receptors. Finally, it explains the concepts of spare receptors, desensitization, and the different types of antagonism - competitive and noncompetitive.
Pharmacodynamics By Dr Debasish Pradhangundu333pappu
This document discusses pharmacodynamics and the mechanisms of drug action. It describes how drugs can act through physical/chemical properties, stimulation, depression, irritation, replacement or cytotoxic effects. However, most drugs act by interacting with biomolecules like enzymes, ion channels, transporters or receptors. The four main types of receptor-mediated drug actions are agonism, antagonism, partial agonism, and inverse agonism. Downstream effects are mediated through four major transduction pathways: G-protein coupled receptors, receptors with intrinsic ion channels, enzyme-linked receptors, and transcription factors.
This document discusses pharmacodynamics, which is the study of how drugs act on the body and their effects. It describes how drugs can have therapeutic or adverse effects by stimulating, depressing, or replacing certain processes. The main targets of drugs are receptors, ion channels, enzymes, and transporter proteins. Receptors are sites that recognize signals and initiate responses. The document outlines different types of receptors like G-protein coupled, ion channel, enzyme, and nuclear receptors. It also discusses concepts like agonists, antagonists, efficacy, potency, dose-response curves, therapeutic index, and synergistic or antagonistic drug interactions.
- Drug receptors, also known as drug targets, are cellular macromolecules or complexes that drugs interact with to elicit a cellular response and change cell function.
- There are various classifications of receptors including pharmacological, biochemical, molecular, anatomical, and GPCR classifications.
- The two main types of receptors are ligand-gated ion channels and G protein-coupled receptors. Ligand-gated ion channels allow ion flow through the cell membrane in response to ligand binding, while GPCRs signal via G proteins to activate intracellular effector mechanisms.
This document discusses pharmacodynamics, which is how drugs act on the body through their mechanisms of action and effects. It provides details on the molecular aspects of specific drug action, including the main targets such as DNA, microbial organelles, and target macroproteins like receptors, ion channels, enzymes, and carrier molecules. Drugs can act through specific binding to these targets or through non-specific effects. The summary describes the four main types of receptors - ionotropic, G-protein coupled, tyrosine kinase-linked, and nuclear receptors - and how they mediate drug effects through different intracellular signaling pathways and timescales. Dose-response relationships and factors affecting drug concentration at the site of action are also introduced.
This document provides an overview of receptors in drug design. It begins by discussing the historical concept of receptors proposed by Langley and Ehrlich. Key terms like ligand, affinity, intrinsic activity, and signal transduction are introduced. The molecular biology of receptors is explained, including their structure as membrane proteins with binding sites, and mechanisms of signal transduction like controlling ion channels or activating signal proteins. Different types of receptor-ligand interactions are covered, such as those between agonists, antagonists, irreversible antagonists, and allosteric modulators. Finally, major receptor theories including Clark's occupancy theory, two-state model, and rate theory are summarized.
This document discusses drug receptor interactions. It defines a receptor as the specific cellular component that a drug binds to produce its pharmacological effects. There are four primary receptor families: ligand gated ion channels, G-protein coupled receptors, enzyme-linked receptors, and intracellular receptors. The document discusses several important interactions involved in drug-receptor complexes, including covalent bonds, ionic interactions, hydrogen bonding, charge transfer interactions, hydrophobic interactions, and van der Waals forces. It provides examples to illustrate how each interaction type can contribute to a drug binding to and activating its receptor.
This document discusses theories of drug receptor interaction. It describes the occupation theory which states that pharmacological effect is proportional to the number of occupied receptors. It also discusses the rate theory, induced fit theory, macromolecular perturbation theory, activation-aggregation theory, and two-state model of receptor activation. Each theory provides a different perspective on how drugs interact with receptors and elicit biological responses.
This document discusses pharmacodynamics and the different types of protein targets that drugs can bind to in order to produce pharmacological responses, including receptors, enzymes, carriers, and ion channels. It focuses on drug receptors, describing them as target molecules that drugs must bind to in order to elicit effects. There are four main types of receptors: ligand-gated ion channels, G protein-coupled receptors, kinase-linked receptors, and nuclear receptors. The document provides details on the molecular structures and mechanisms of ligand-gated ion channels and G protein-coupled receptors.
A power point presentation on Pharmacodynamics (what drug does to the body) suitable for undergraduate medical students beginning to study Pharmacology
This document discusses the importance of understanding the mechanism of drug action. It explains that pharmacodynamics is the study of how drugs work in the body and affect it biochemically and physiologically. Understanding these mechanisms is important for several reasons: 1) It helps build trust between patients and their doctors by allowing doctors to explain how the drug is working, 2) Patients who understand their treatment are more likely to participate in managing their disease, and 3) Knowing the mechanisms increases doctors' confidence that drugs are being used appropriately and helps avoid interactions and adverse effects.
Outcomes:
Students must be able to demonstrate knowledge of pharmacodynamics under the following headings:
• Definition
• Structurally specific drugs
• Structurally non-specific drugs
• Receptor binding
• Agonists and antagonists
• Intracellular receptors
• Enzyme receptors
• Transport carrier receptors
• Neurotransmitters
Chirality refers to geometric isomers that are non-superimposable mirror images. Enantiomers are a type of chiral isomer that are biologically significant as biomolecules and receptors are often chiral. The two enantiomers can have different pharmacokinetic and pharmacodynamic properties, including differences in absorption, distribution, metabolism, excretion, efficacy and toxicity. Developing single enantiomers rather than racemic mixtures can improve safety profiles and therapeutic efficacy of drugs. Separation techniques continue to advance in order to isolate desirable single enantiomers from mixtures.
The document discusses receptors and their interaction with ligands and drugs. It defines receptors as macromolecules, usually proteins, that bind ligands and initiate a cellular response. Receptors exist in two states - active and inactive - and bind agonists, antagonists, and other ligands. Agonists activate the receptor and initiate a response, while antagonists bind without activating the receptor. The affinity and efficacy of drug binding determines whether it acts as an agonist or antagonist. Competitive antagonists can be overcome by high doses of agonists, while non-competitive antagonists induce a conformational change preventing agonist binding. The document outlines the importance of receptor studies for drug development and action.
1. The document discusses the structural activity relationships of various anticonvulsant drug classes including hydantoins, barbiturates, benzodiazepines, valproic acid, and succinimides. Certain aromatic or alkyl substitutions are required for optimal activity within each class.
2. New anticonvulsant compounds currently in clinical trials are discussed, such as AWD 131-138, retigabine, rufinamide, and others. These compounds have novel mechanisms of action such as blockade of voltage-activated calcium channels or increasing potassium conductance in neurons.
3. The structural features required for anticonvulsant activity are compared between drug classes to understand how chemical modifications
Receptors are membrane-bound proteins that receive chemical signals from outside the cell. When a messenger binds to the receptor, it causes a conformational change in the receptor that triggers downstream effects, ultimately resulting in changes in cellular chemistry. There are three main types of receptors: ion channel receptors, G-protein coupled receptors, and kinase-linked receptors. Ion channel receptors directly open ion channels, GPCRs activate intracellular signaling pathways, and kinase receptors directly activate intracellular kinase enzymes. Together, these receptor types facilitate cell-cell communication and control of gene expression.
- Agonists, partial agonists, and inverse agonists are drug ligands that interact with receptors to elicit different cellular responses. Agonists mimic the effects of endogenous ligands, partial agonists produce submaximal effects, and inverse agonists stabilize receptors in their inactive state.
- The two-state receptor model describes receptors existing in two conformational states (active and inactive) that ligands differentially stabilize. Biased agonism occurs when ligands preferentially activate different intracellular signaling pathways.
- Key concepts include efficacy, intrinsic activity, and constitutive receptor activity. Partial agonists have efficacy below full agonists and produce submaximal responses even at full receptor occupancy. Inverse agonists suppress constitutive receptor activity.
Pharmacodynamics, mechanism of drug actionAsma Aslam
complete information on receptors and their mechanism of actions... briefly discussed about pharmacodynamics and up regulation and desensitization of receptors,
This document discusses pharmacodynamics in anesthesia. It describes how drugs affect the body through mechanisms of action, drug-receptor interactions, and dose-response relationships. Factors like age, genetics, disease states can impact pharmacodynamics. Drugs act through receptor-mediated actions, with receptors on cell membranes determining effects. Receptors include ion channels, G-protein coupled receptors, and those activating protein kinases or transcription. The efficacy and potency of drugs are also discussed in relation to agonists, antagonists, competitive vs. non-competitive antagonism. Therapeutic indices compare median effective and toxic doses. Pharmacodynamics are affected by patient factors and drug properties.
Pharmacodynamics is the study of how drugs act on the body and biological system, including receptor interactions and mechanisms of action. Most drugs act by binding to receptors, and spare receptors allow a maximal response even when not all receptors are occupied, as only a portion need to be bound. Agonists activate receptors to produce a response, with full agonists having maximal efficacy and partial agonists having less efficacy than full agonists. Antagonists block the action of agonists without activating the receptors themselves.
This document contains a list of 100 single word substitutions for common phrases or concepts. Some examples provided include "rusticate" as a substitute for relaxing in the countryside, "elite" for the most capable part of a group, and "parvenu" for one who flaunts newly acquired wealth. A wide variety of topics are covered, including personality types, occupations, locations, legal terms, relationships, and more. Concise single word alternatives are given to concisely describe each concept.
Final course module for may 2010 pharmacology-iii - copy - copypctebpharm
This document provides information on the Pharmacology-III course for 7th semester B.Pharm students. The 40-lecture course covers drugs acting on the gastrointestinal tract, endocrine system, chemotherapy, and toxicology principles. Assessment includes assignments, presentations, tests, and semester exams. Students must maintain 75% attendance and follow instructions for assignments, presentations, and practicals to be eligible to appear for exams. The course aims to provide in-depth knowledge of drug pharmacokinetics, pharmacodynamics, and therapeutic and toxic effects.
This document discusses pharmacodynamics, which is the study of how drugs act on the body and their effects. It describes how drugs can have therapeutic or adverse effects by stimulating, depressing, or replacing certain processes. The main targets of drugs are receptors, ion channels, enzymes, and transporter proteins. Receptors are sites that recognize signals and initiate responses. The document outlines different types of receptors like G-protein coupled, ion channel, enzyme, and nuclear receptors. It also discusses concepts like agonists, antagonists, efficacy, potency, dose-response curves, therapeutic index, and synergistic or antagonistic drug interactions.
- Drug receptors, also known as drug targets, are cellular macromolecules or complexes that drugs interact with to elicit a cellular response and change cell function.
- There are various classifications of receptors including pharmacological, biochemical, molecular, anatomical, and GPCR classifications.
- The two main types of receptors are ligand-gated ion channels and G protein-coupled receptors. Ligand-gated ion channels allow ion flow through the cell membrane in response to ligand binding, while GPCRs signal via G proteins to activate intracellular effector mechanisms.
This document discusses pharmacodynamics, which is how drugs act on the body through their mechanisms of action and effects. It provides details on the molecular aspects of specific drug action, including the main targets such as DNA, microbial organelles, and target macroproteins like receptors, ion channels, enzymes, and carrier molecules. Drugs can act through specific binding to these targets or through non-specific effects. The summary describes the four main types of receptors - ionotropic, G-protein coupled, tyrosine kinase-linked, and nuclear receptors - and how they mediate drug effects through different intracellular signaling pathways and timescales. Dose-response relationships and factors affecting drug concentration at the site of action are also introduced.
This document provides an overview of receptors in drug design. It begins by discussing the historical concept of receptors proposed by Langley and Ehrlich. Key terms like ligand, affinity, intrinsic activity, and signal transduction are introduced. The molecular biology of receptors is explained, including their structure as membrane proteins with binding sites, and mechanisms of signal transduction like controlling ion channels or activating signal proteins. Different types of receptor-ligand interactions are covered, such as those between agonists, antagonists, irreversible antagonists, and allosteric modulators. Finally, major receptor theories including Clark's occupancy theory, two-state model, and rate theory are summarized.
This document discusses drug receptor interactions. It defines a receptor as the specific cellular component that a drug binds to produce its pharmacological effects. There are four primary receptor families: ligand gated ion channels, G-protein coupled receptors, enzyme-linked receptors, and intracellular receptors. The document discusses several important interactions involved in drug-receptor complexes, including covalent bonds, ionic interactions, hydrogen bonding, charge transfer interactions, hydrophobic interactions, and van der Waals forces. It provides examples to illustrate how each interaction type can contribute to a drug binding to and activating its receptor.
This document discusses theories of drug receptor interaction. It describes the occupation theory which states that pharmacological effect is proportional to the number of occupied receptors. It also discusses the rate theory, induced fit theory, macromolecular perturbation theory, activation-aggregation theory, and two-state model of receptor activation. Each theory provides a different perspective on how drugs interact with receptors and elicit biological responses.
This document discusses pharmacodynamics and the different types of protein targets that drugs can bind to in order to produce pharmacological responses, including receptors, enzymes, carriers, and ion channels. It focuses on drug receptors, describing them as target molecules that drugs must bind to in order to elicit effects. There are four main types of receptors: ligand-gated ion channels, G protein-coupled receptors, kinase-linked receptors, and nuclear receptors. The document provides details on the molecular structures and mechanisms of ligand-gated ion channels and G protein-coupled receptors.
A power point presentation on Pharmacodynamics (what drug does to the body) suitable for undergraduate medical students beginning to study Pharmacology
This document discusses the importance of understanding the mechanism of drug action. It explains that pharmacodynamics is the study of how drugs work in the body and affect it biochemically and physiologically. Understanding these mechanisms is important for several reasons: 1) It helps build trust between patients and their doctors by allowing doctors to explain how the drug is working, 2) Patients who understand their treatment are more likely to participate in managing their disease, and 3) Knowing the mechanisms increases doctors' confidence that drugs are being used appropriately and helps avoid interactions and adverse effects.
Outcomes:
Students must be able to demonstrate knowledge of pharmacodynamics under the following headings:
• Definition
• Structurally specific drugs
• Structurally non-specific drugs
• Receptor binding
• Agonists and antagonists
• Intracellular receptors
• Enzyme receptors
• Transport carrier receptors
• Neurotransmitters
Chirality refers to geometric isomers that are non-superimposable mirror images. Enantiomers are a type of chiral isomer that are biologically significant as biomolecules and receptors are often chiral. The two enantiomers can have different pharmacokinetic and pharmacodynamic properties, including differences in absorption, distribution, metabolism, excretion, efficacy and toxicity. Developing single enantiomers rather than racemic mixtures can improve safety profiles and therapeutic efficacy of drugs. Separation techniques continue to advance in order to isolate desirable single enantiomers from mixtures.
The document discusses receptors and their interaction with ligands and drugs. It defines receptors as macromolecules, usually proteins, that bind ligands and initiate a cellular response. Receptors exist in two states - active and inactive - and bind agonists, antagonists, and other ligands. Agonists activate the receptor and initiate a response, while antagonists bind without activating the receptor. The affinity and efficacy of drug binding determines whether it acts as an agonist or antagonist. Competitive antagonists can be overcome by high doses of agonists, while non-competitive antagonists induce a conformational change preventing agonist binding. The document outlines the importance of receptor studies for drug development and action.
1. The document discusses the structural activity relationships of various anticonvulsant drug classes including hydantoins, barbiturates, benzodiazepines, valproic acid, and succinimides. Certain aromatic or alkyl substitutions are required for optimal activity within each class.
2. New anticonvulsant compounds currently in clinical trials are discussed, such as AWD 131-138, retigabine, rufinamide, and others. These compounds have novel mechanisms of action such as blockade of voltage-activated calcium channels or increasing potassium conductance in neurons.
3. The structural features required for anticonvulsant activity are compared between drug classes to understand how chemical modifications
Receptors are membrane-bound proteins that receive chemical signals from outside the cell. When a messenger binds to the receptor, it causes a conformational change in the receptor that triggers downstream effects, ultimately resulting in changes in cellular chemistry. There are three main types of receptors: ion channel receptors, G-protein coupled receptors, and kinase-linked receptors. Ion channel receptors directly open ion channels, GPCRs activate intracellular signaling pathways, and kinase receptors directly activate intracellular kinase enzymes. Together, these receptor types facilitate cell-cell communication and control of gene expression.
- Agonists, partial agonists, and inverse agonists are drug ligands that interact with receptors to elicit different cellular responses. Agonists mimic the effects of endogenous ligands, partial agonists produce submaximal effects, and inverse agonists stabilize receptors in their inactive state.
- The two-state receptor model describes receptors existing in two conformational states (active and inactive) that ligands differentially stabilize. Biased agonism occurs when ligands preferentially activate different intracellular signaling pathways.
- Key concepts include efficacy, intrinsic activity, and constitutive receptor activity. Partial agonists have efficacy below full agonists and produce submaximal responses even at full receptor occupancy. Inverse agonists suppress constitutive receptor activity.
Pharmacodynamics, mechanism of drug actionAsma Aslam
complete information on receptors and their mechanism of actions... briefly discussed about pharmacodynamics and up regulation and desensitization of receptors,
This document discusses pharmacodynamics in anesthesia. It describes how drugs affect the body through mechanisms of action, drug-receptor interactions, and dose-response relationships. Factors like age, genetics, disease states can impact pharmacodynamics. Drugs act through receptor-mediated actions, with receptors on cell membranes determining effects. Receptors include ion channels, G-protein coupled receptors, and those activating protein kinases or transcription. The efficacy and potency of drugs are also discussed in relation to agonists, antagonists, competitive vs. non-competitive antagonism. Therapeutic indices compare median effective and toxic doses. Pharmacodynamics are affected by patient factors and drug properties.
Pharmacodynamics is the study of how drugs act on the body and biological system, including receptor interactions and mechanisms of action. Most drugs act by binding to receptors, and spare receptors allow a maximal response even when not all receptors are occupied, as only a portion need to be bound. Agonists activate receptors to produce a response, with full agonists having maximal efficacy and partial agonists having less efficacy than full agonists. Antagonists block the action of agonists without activating the receptors themselves.
This document contains a list of 100 single word substitutions for common phrases or concepts. Some examples provided include "rusticate" as a substitute for relaxing in the countryside, "elite" for the most capable part of a group, and "parvenu" for one who flaunts newly acquired wealth. A wide variety of topics are covered, including personality types, occupations, locations, legal terms, relationships, and more. Concise single word alternatives are given to concisely describe each concept.
Final course module for may 2010 pharmacology-iii - copy - copypctebpharm
This document provides information on the Pharmacology-III course for 7th semester B.Pharm students. The 40-lecture course covers drugs acting on the gastrointestinal tract, endocrine system, chemotherapy, and toxicology principles. Assessment includes assignments, presentations, tests, and semester exams. Students must maintain 75% attendance and follow instructions for assignments, presentations, and practicals to be eligible to appear for exams. The course aims to provide in-depth knowledge of drug pharmacokinetics, pharmacodynamics, and therapeutic and toxic effects.
This document lists various diseases and disorders and their corresponding drug of choice for treatment. Some of the diseases and drugs mentioned include: MRSA infection treated with vancomycin; malaria in pregnancy treated with chloroquine; whooping cough or pertussis treated with erythromycin; Kawasaki disease treated with IV immunoglobulin; warfarin overdose treated with vitamin K; and heparin overdose treated with protamine. It provides an overview of commonly used drugs to treat a wide range of medical conditions.
This document provides definitions for common English idioms organized alphabetically from A to K. Each idiom is defined and an example sentence is given to illustrate its meaning. The idioms cover a wide range of topics from emotions and behaviors to luck and situations. In under 3 sentences, this summary highlights the content and structure of the document.
The Philippine Pharmacists Licensure Exam is composed of six modules covering different categories: Pharmaceutical Chemistry (20%), Pharmacognosy (17.5%), Practice of Pharmacy (17.5%), Pharmacology and Pharmacokinetics (15%), Pharmaceutics (17.5%), and Quality Assurance and Quality Control (15%). Each module focuses on specific topics within its category and questions are gathered from key sources and textbooks.
Pharmacology is study of the substances which interact with living system by activating or inhibiting normal body processes. It includes physical and chemical properties, biochemical and physiological effects, mechanism of action, therapeutic uses and adverse effects of drugs.
This document discusses various common idioms in English:
- "A piece of cake" means something is very easy to do
- "As easy as ABC" and "as easy as pie" both describe tasks that are very simple
- A "hard/tough nut to crack" refers to a difficult problem or person
- A "ball of fire" is a person with great energy
- "As busy as a bee" means to be very busy or active
- "Have butterflies in your stomach" feels very nervous
- "Raining cats and dogs" describes heavy rain
- "Cost an arm and a leg" means something is very expensive
- "Over the moon" means
The document provides information about pharmacology and related topics. It discusses the definition of pharmacology as the study of drugs and their actions on the body. It also covers key concepts such as pharmacokinetics, pharmacodynamics, drug dosage forms, routes of administration, absorption, distribution, metabolism, excretion, and factors that influence drug response.
Drug Receptors intercaction and Drug antagonism : Dr Rahul Kunkulol's Power p...Rahul Kunkulol
1. The document discusses various types of drug receptors and receptor superfamilies including ligand-gated ion channels, G-protein coupled receptors, kinase-linked receptors, and nuclear receptors.
2. It describes the mechanisms of drug-receptor interactions and signal transduction pathways involving second messengers like cAMP, IP3, DAG, Ca2+, and nitric oxide.
3. The concepts of agonism, antagonism, partial agonism, and theories of drug-receptor binding like the two-state model are explained. Different types of antagonism like competitive and non-competitive are also summarized.
Pharmacodynamics is the study of how drugs act on the body and their mechanisms of action. It involves drug-receptor interactions and explains the relation between drug effects. Pharmacodynamics provides a basis for rational drug use and design. Drugs can act through stimulation, depression, irritation, replacement or cytotoxic effects on cells. Their main targets are receptors, ion channels, enzymes, and transporter proteins. Understanding drug-receptor interactions is important for explaining drug effects and determining their potency and efficacy. Drug interactions can enhance or reduce the effects of drugs and should be considered when administering multiple medications.
1) Receptors are specific macromolecular proteins that interact with drugs to produce changes in biological systems. Receptors have drug-binding sites and biologically active sites, and determine quantitative drug effects. Receptors mediate actions of agonists and antagonists.
2) Agonists fully or partially activate receptors to produce responses resembling endogenous ligands. Full agonists have maximal efficacy while partial agonists have submaximal efficacy. Inverse agonists decrease constitutive receptor activity.
3) Some drugs act through non-receptor mediated mechanisms like interfering with ion passage through cell membranes, inhibiting enzymes or transport processes, or directly interacting with molecules outside cells.
1. Pharmacology is the study of how drugs act on biological systems and their therapeutic and toxic effects.
2. The study includes drug absorption, distribution, metabolism, and excretion by the body (pharmacokinetics) as well as the biochemical and physiological effects of drugs on the body (pharmacodynamics).
3. Key areas of pharmacology include understanding drug-receptor interactions, adverse drug reactions, pharmacogenomics, clinical trials, and drug safety monitoring.
Advanced Medicinal Chemistry of GPCR Receptorsaurabh gupta
Contents:-
Introduction
Structure of G-protein
Signal Molecules / Ligands of GPCRs
G- Protein Mediated Pathways
Receptor Site Theories
Forces involved in drug receptor interactions
This document discusses different types of receptors including ligand gated ion channels, G-protein coupled receptors, enzyme linked receptors, and nuclear receptors. It describes receptor-drug interactions including affinity, intrinsic activity, efficacy, and potency. It defines different types of agonism and antagonism. The document provides examples and details on various receptor types and their mechanisms of action. In conclusion, extensive receptor pharmacology research has led to new drug targets, but more remains to be discovered about new receptor types and orphan receptors to further advance treatment options.
The document discusses drug pharmacodynamics and mechanisms of action. It describes two main types of mechanisms - receptor-mediated and non-receptor mechanisms. Receptor-mediated mechanisms involve drug-receptor interactions that can result in various effects depending on whether the drug is an agonist, antagonist, partial agonist, or inverse agonist. Non-receptor mechanisms involve direct physical or chemical reactions between the drug and other molecules in the body. The document also discusses receptor types, models of drug-receptor interactions, factors that influence drug response, and potential adverse effects of drug interactions and reactions.
This document provides an overview of drug mechanism of action. It discusses pharmacodynamics concepts like drug receptors, quantitative drug-receptor interactions, and factors that can influence drug action. It describes several mechanisms of drug action including altering endogenous ligand concentrations, regulating ion transport, and activating cellular signaling pathways. Finally, it discusses two major structural families of physiological receptors: G protein-coupled receptors and ligand-gated ion channels.
Mechanism of drug action & factor modifying drug actionDipak Bari
This document discusses pharmacodynamics and the mechanisms of drug action. It explains that pharmacodynamics is the study of biochemical and physiological effects of drugs and their mechanisms of action. The key mechanisms discussed are: receptor-mediated binding, non-receptor mediated effects, enzyme inhibition or stimulation, and physical or chemical properties. Factors that can modify a drug's action like body weight, age, drug interactions, and tolerance are also summarized.
Pharmacodynamics describes how drugs act on the body, including their mechanisms of action and effects. There are several types of drug effects, including stimulation, inhibition, replacement, and irritation. Drugs can act through physical, chemical, or biochemical mechanisms, often by interacting with receptors. The main receptor families are those coupled to ion channels, G protein-coupled receptors, enzymatic receptors, and intracellular receptors. Antagonists can decrease or abolish the effects of other drugs through competitive or non-competitive mechanisms.
THIS PPT INCLUDE PHARMACODYNAMICS AND THIS PPT IS VERY USEFUL FOR (MBBS,BDS ) STUDENTS ,POSTGRADUATE STUDENT (MD,MDS,Phd) STUDENTS TO UNDERSTAND PHARMACODYNAMICS.
This document discusses pharmacodynamics and mechanisms of drug action. It begins by defining pharmacodynamics as the study of drug effects and how they are produced. It then describes the main types of drug action as stimulation, depression, replacement, and cytotoxic effects. The major mechanisms of drug action are interactions with receptors, enzymes, ion channels, and transporters. Receptors recognize drugs and initiate responses, while enzymes and ion channels can be inhibited or activated by drugs. The document provides several examples to illustrate these concepts and mechanisms of drug action.
This document discusses pharmacodynamics and drug receptors. It defines pharmacodynamics as the study of pharmacological drug effects and mechanisms of action. The objectives are to understand drug-target cell interactions and characterize a drug's full scope and sequence of action, providing a basis for rational therapeutic use and new drug development. It describes different types of drug receptors, including ligand-gated ion channels, G-protein coupled receptors, and intracellular receptors. It also discusses concepts such as agonists, antagonists, and partial agonists that act on receptors to elicit responses or block responses.
Preclinical toxicology studies are conducted in vitro and in vivo in animals to demonstrate a compound's safety before human studies. However, toxicity cannot be fully predicted and compounds still fail in clinical trials for various reasons including mechanism-based pharmacology, reactive metabolites, interactions with other receptors or substances, and idiosyncratic toxicity. Careful consideration of a compound's structure is important to avoid potential toxicity issues like reactive functional groups that could form toxic metabolites or unintended interactions with proteins like the hERG potassium channel. Drug-drug interactions are also a concern if one drug inhibits the metabolic enzymes of another.
Preclinical toxicology studies are conducted in vitro and in vivo in animals to demonstrate a compound's safety before human studies. However, toxicity cannot be fully predicted and compounds still fail in clinical trials for various reasons including mechanism-based pharmacology, reactive metabolites, interactions with other receptors or substances, and idiosyncratic toxicity. Careful consideration of a compound's structure is important to avoid potential toxicity issues like reactive functional groups that could form toxic metabolites or unintended interactions with proteins like the hERG potassium channel. Drug-drug interactions are also a concern if one drug inhibits the metabolic enzymes of another.
Preclinical toxicology studies are conducted in vitro and in vivo in animals to demonstrate a compound's safety before human studies. However, toxic effects are still sometimes observed in human clinical trials despite animal studies. Reasons for failure include mechanism-based pharmacology, reactive metabolites, interactions with other receptors or substances, and idiosyncratic toxicity. Careful consideration of a compound's potential to form reactive metabolites, interact with targets like hERG potassium channels, or inhibit cytochrome P450 enzymes can help predict and avoid toxicities during drug development.
This document discusses mechanisms of drug action and pharmacodynamics. It covers several key topics:
1. Drugs can act through specific receptor interactions or through non-specific physicochemical properties. Receptor interactions involve binding to receptors that trigger biochemical responses.
2. There are several types of receptors that drugs can act on, including ion channels, G-protein coupled receptors, and intracellular receptors.
3. The effects of drugs are determined by their affinity for receptors and intrinsic activity. Agonists have both while antagonists only have affinity.
4. When drugs are combined, their effects may be additive, potentiated, or antagonistic depending on if they act through similar or different mechanisms and sites of
This document defines key terms related to drug receptor interactions. It discusses how drugs produce their effects by binding to receptors, and defines agonists as drugs that activate receptors through both affinity and intrinsic activity. Antagonists are defined as drugs that block the action of other drugs. The document also outlines different types of antagonism and pharmacologic drug actions. Finally, it summarizes several hypotheses regarding how drugs interact with receptors, including the lock and key hypothesis.
1. Pharmacodynamics is the study of drug effects and how drugs produce their effects.
2. Drugs can produce effects through stimulation, depression, irritation, replacement, or cytotoxic action on cells. The majority of drugs interact with specific protein targets like enzymes, ion channels, transporters, and receptors.
3. Drug interactions with targets can be agonistic, antagonistic, or otherwise modulate the target's function. Understanding a drug's potency, efficacy, therapeutic index, and interactions provides insight into its pharmacological effects.
The document provides an overview of NMR spectroscopy techniques. It discusses key topics like nuclear magnetism, nuclear magnetic resonance, relaxation, magnetization vectors, Bloch equations, NMR spectra, chemical shift, spin-spin coupling, and instrumental methods. Specifically, it covers pulse Fourier transform NMR spectroscopy, double resonance techniques, measurement of carbon-carbon relaxation times, and two-dimensional NMR experiments.
This document provides an overview of 2D NMR spectroscopy and COSY NMR experiments. It discusses how 2D NMR addresses limitations of 1D NMR for analyzing complex protein spectra by introducing additional spectral dimensions. COSY NMR specifically correlates hydrogen atoms that are directly bonded to each other, showing their interactions on a grid plot with chemical shifts on both axes. Interpreting COSY spectra involves identifying off-diagonal peaks that indicate correlations between different hydrogen atoms.
This document provides an introduction to nuclear magnetic resonance (NMR) spectroscopy. It begins with an overview of NMR and spectroscopy. It then reviews common units used in NMR such as time, temperature, magnetic field strength, energy, and frequency. The document consists of introductory chapters that cover topics like the basics of NMR, mathematics relevant to NMR, spin physics, and energy levels. It provides explanations of fundamental NMR concepts such as spin, magnetic moments, energy states, resonance frequency, and relaxation times T1 and T2. The overall document serves as a comprehensive primer on basic NMR principles.
Brent Yoder isolated and characterized several new cytotoxic natural products from plants collected in Madagascar and Suriname as part of his dissertation research. From a Tambourissa species bark extract, he isolated a new hydroxybutanolide called tambouranolide, which has a unique long hydrocarbon chain. From Macaranga alnifolia fruit, he obtained four new prenylated stilbenes, one new geranylated dihydroflavanol, and five known compounds. Two of the new stilbenes showed high cytotoxicity. From Cerbera manghas bark and leaves, he isolated the known iridoid cerbinal and the known cardiac glycoside neriifolin, both of which exhibited
This document is an academic thesis presented by Marcelo A. Dávila Cabrera at Lund University in Sweden. The thesis presents results from phytochemical studies of four Bolivian plants, including Senecio clivicolus, Prumnopitys exigua, Baccharis polycephala, and Podocarpus parlatorei. Various chromatographic and spectroscopic techniques were used to isolate and characterize secondary metabolites from the plants. The isolated compounds are described in four papers that are included in the thesis.
This dissertation describes the isolation and structural elucidation of natural products from various plant materials. Chromatographic and spectroscopic techniques were used to isolate and determine the structures of terpenes, terpenoids, and other secondary metabolites. Several hitherto unknown compounds were characterized, including (+)-axinyssene from Otostegia integrifolia, guaia-1(10),11-diene and guaia-9,11-diene from Peucedanum tauricum, four sesquiterpenoids from Chloranthus spicatus, isoligustilide from Meum athamanticum, and two diterpenes and four sesquiterpenes from Rad
The document summarizes a doctoral dissertation which investigated terpenoid plant metabolites from four medicinal plants. Key findings include:
- Two new sesquiterpenes and a novel triterpene were isolated from Kaunia lasiophthalma and tested for anticancer activity. Several exhibited potent anticancer effects but also cytotoxicity.
- Extracts of Trixis antimenorrhoea and Lantana balansae showed antileishmanial activity. Two new metabolites were isolated from T. antimenorrhoea, while L. balansae yielded several known compounds and some new classes of metabolites.
- Three novel macrocyclic monoterpene glycosides were
This study investigated the antimicrobial activity of Cinnamomum iners leaves extract and isolated compounds. The ethyl acetate fraction showed the highest activity against methicillin-resistant Staphylococcus aureus and Escherichia coli. Through bioautography and spectroscopic analysis, the active compound was isolated and identified as xanthorrhizol. Xanthorrhizol exhibited antimicrobial activity against both Gram-positive and Gram-negative pathogens such as MRSA and E. coli. This provides evidence that C. iners leaves and xanthorrhizol could be potential sources of antimicrobial agents.
Tesis ini meneliti isolasi dan elusidasi struktur senyawa antioksidan dan penghambat xantin oksidase dari buah andaliman (Zanthoxylum acanthopodium DC.). Ekstrak n-butanol buah andaliman diisolasi menggunakan kromatografi kolom dan diperoleh dua senyawa yaitu ZAB-1 dan ZAB-2. ZAB-1 dan ZAB-2 diidentifikasi sebagai terpenoid polar berdasarkan hasil spektroskopi. Kedua senyawa tersebut mem
Gerhana matahari terjadi ketika bulan berada di antara bumi dan matahari sehingga menghalangi sinar matahari, menyebabkan kegelapan sementara di bagian permukaan bumi tertentu. Gerhana total berbentuk lingkaran dengan diameter maksimal 270 km dan yang terpanjang pernah terjadi pada tahun 1955 selama 7,2 menit.
Gerhana bulan terjadi ketika bulan memasuki bayangan bumi (umbra) yang menyebabkan bulan menjadi gelap total atau sebagian, dimulai dari masuknya bagian bulan ke dalam bayangan yang kurang gelap (penumbra) hingga keluarnya bulan dari penumbra dan kembali normal.
1. Pharmacodynamics
Prof. Dr. Öner Süzer
Cerrahpaşa Medical Faculty
Department of Pharmacology and Clinical Pharmacology
www.onersuzer.com
Last updated: 13.05.2010
English Pharmacology Textbooks
2
2
1
2. 3
3
Contents of the lecture
Pharmacodynamics deals with what drugs do for human
body.
Subjects to be discussed:
Mechanisms of drug actions
Drug-receptor interaction
Dose (concentration) - effect relationship
Factors that modify drug actions and drug interactions
Adverse drug reactions (drug toxicology)
4
4
2
3. Molecular targets for drugs I
Enzymes such as:
Acetylcholine esterase, choline acetyltransferase,
cyclooxygenase, xanthine oxidase, angiotensin-converting
enzyme, carbonic anhydrase, HMG-CoA reductase, Dopa
decarboxylase, monoamine oxidase, dihydrofolate
reductase, DNA polymerase…
5
5
6
6 Rang and Dale’s Pharmacology, 6th edition
3
4. 7
7 Rang and Dale’s Pharmacology, 6th edition
Molecular targets for drugs II
Transport proteins such as:
Choline transporter at terminal neuron, vesicular
norepinefrine uptake, norepinefrine reuptake1, proximal
tubular secretion (for weak acids), Na+/K+/2Cl- cotransport
at loop of Henle, Na+/K+-ATPase pump, proton pump at
gastric mucosa...
8
8
4
5. 9
9 Rang and Dale’s Pharmacology, 6th edition
10
10 Rang and Dale’s Pharmacology, 6th edition
5
6. Molecular targets for drugs III
Ion channels such as:
Receptor or voltage gated Na+, K+, Ca2+, Cl- channels.
11
11
12
12 Rang and Dale’s Pharmacology, 6th edition
6
7. 13
13 Rang and Dale’s Pharmacology, 6th edition
Molecular targets for drugs IV
Receptors such as:
Acetylcholine receptors, adrenergic receptors, histamine
receptors, opioid receptors, serotonine receptors, dopamin
receptors, prokineticin receptors, insulin receptors,
estrogen receptors, progesterone receptors, ryanodine
receptors…
14
14
7
8. 15
15 Rang and Dale’s Pharmacology, 6th edition
16
16 Rang and Dale’s Pharmacology, 6th edition
8
9. Receptors
The effects of most drugs result from their interaction with
macromolecular components of the organism. These
interactions alter the function of the pertinent component
and thereby initiate the biochemical and physiological
changes that are characteristic of the response to the drug.
The term receptor denotes the component of the organism
with which the chemical agent is presumed to interact.
For recent and updated information please refer
http://iuphar-db.org
17
17 Goodman & Gilman Pharmacology, 11th edition
The concept of drugs acting on receptors generally is
credited to John Langley (1878). While studying the
antagonistic effects of atropine against pilocarpine -
induced salivation, Langley observed, "There is some
substance or substances in the nerve ending or gland cell
with which both atropine and pilocarpine are capable of
forming compounds." He later referred to this factor as a
"receptive substance." The word receptor was introduced
in 1909 by Paul Ehrlich. Ehrlich postulated that a drug
could have a therapeutic effect only if it has the "right sort
of affinity." Ehrlich defined a receptor in functional terms:
"… that combining group of the protoplasmic molecule to
which the introduced group is anchored will hereafter be
termed receptor."
18
18 Goodman & Gilman Pharmacology, 11th edition
9
10. Drug-Receptor Binding and Agonism I
A receptor can exist in at least
two conformational states,
active (Ra), and inactive (Ri). If
these states are in equilibrium
and the inactive state
predominates in the absence
of drug, then the basal signal
output will be low.
The extent to which the
equilibrium is shifted toward
the active state is determined
by the relative affinity of the
drug for the two
conformations.
19
19 Goodman & Gilman Pharmacology, 11th edition
Drug-Receptor Binding and Agonism II
A drug that has a higher affinity for the active conformation
than for the inactive conformation will drive the equilibrium
to the active state and thereby activate the receptor. Such a
drug will be an agonist.
A full agonist is sufficiently selective for the active
conformation that at a saturating concentration it will drive
the receptor essentially completely to the active state.
20
20 Goodman & Gilman Pharmacology, 11th edition
10
11. Drug-Receptor Binding and Agonism III
If a different but perhaps structurally similar compound
binds to the same site on R but with only moderately
greater affinity for Ra than for Ri , its effect will be less,
even at saturating concentrations.
A drug that displays such intermediate effectiveness is
referred to as a partial agonist because it cannot promote a
full biological response at any concentration.
In an absolute sense, all agonists are partial; selectivity for
Ra over Ri cannot be total.
21
21 Goodman & Gilman Pharmacology, 11th edition
Antagonism
A drug that binds with equal affinity to either conformation
will not alter the activation equilibrium and will act as a
competitive antagonist of any compound, agonist or
antagonist, that does.
A drug with preferential affinity for Ri actually will produce
an effect opposite to that of an agonist; examples of such
inverse agonists at G protein-coupled receptors (GPCRs)
do exist (e.g., famotidine, losartan, metoprolol, and
risperidone).
22
22 Goodman & Gilman Pharmacology, 11th edition
11
12. 23
23 Goodman & Gilman Pharmacology, 11th edition
24
24 Rang and Dale’s Pharmacology, 6th edition
12
13. 25
25 Rang and Dale’s Pharmacology, 6th edition
Receptor types
26
26
13
14. Type 1. Ligand-gated ion channels
These receptors are located at the membrane. Their celular
effects are mediated via ion channels coupled directly (e.g.
Na+, K+, Ca2+, Cl- channels).
Effect occurs in miliseconds.
Examples: nicotinic acetylcholine receptors, GABAA
receptor, NMDA receptor.
27
27
Ligand-gated ion channels
28
28 Rang and Dale’s Pharmacology, 6th edition
14
15. Type 2. G-protein coupled receptors (GPCR)
These receptors are located at the membrane. Their celular
effects are mediated via G-protein coupled second
messengers.
Effect occurs in seconds.
Examples: muscarinic acetylcholine receptors, adrenergic
receptors, GABAB receptor, metabotropic glutamate
receptor.
29
29
G-protein-coupled receptors
30
30 Rang and Dale’s Pharmacology, 6th edition
15
18. G-protein coupled celular events
35 35
35 Rang and Dale’s Pharmacology, 6th edition
Type 3. kinase-linked receptors
These receptors are located at the membrane. Their celular
effects are mediated via tyrosine kinase or guanylate
cyclase.
Effect occurs in minutes (sometimes in hours).
Examples: Tyrosine kinase-linked, insulin receptor,
cytokine and growth factor (e.g. epidermal and platelet
derived growth factors) receptors; guanylate cyclase
linked, atrial natriuretic factor (ANF) receptor.
Guanylate cyclase related events are mediated via protein
kinase G (PKG).
36
36
18
19. Tyrosine kinase mediated second
messengers
Insulin receptor (when activated tyrosine kinase initiates
various celular events and intracelular cAMP decreases)
Ras/Raf/Mek/MAP kinase pathway is stimulated via growth
factors which are important for cell division and
differentiation
Jak/Stat pathway is stimulated via cytokines which are
responsible for synthesis and release of many
inflammatory mediators
37
37
Kinase-linked receptors
38
38 Rang and Dale’s Pharmacology, 6th edition
19
20. Growth factor (Ras/Raf) pathway
39 39
39 Rang and Dale’s Pharmacology, 6th edition
Cytokine (Jak/Stat) pathway
40
40 Rang and Dale’s Pharmacology, 6th edition
20
21. Type 4. Cytoplasmic or nuclear receptors
Steroid hormon, vitamine D and retinoic acid receptors are
located at the cytoplasm. These hormons effect on gene
transcription on DNA via (heat shock proteins, HSP).
Tyroid hormon receptors are located at the nucleus.
Effect depends on new protein synthesis and occurs in
hours.
Synthesis of effector proteins controlled via complex
control cascades.
41
41
Steroid receptors
42
42 Rang and Dale’s Pharmacology, 6th edition
21
24. Dose-response relationship
Quantal dose-response relationship: Effect of drug is “all
or none” (action is either present or absent).
Graded dose-response relationship: Effect of drug is
enhanced with increasing concentration/dosage.
47
47
48
48
24
29. Drug antagonism
Chemical antagonism: Antagonist binds to agonist and
deactivates/neutralizes. Most of the chemical antagonists
are antidotes.
Pharmacological antagonism: Agonist and antagonist
effects directly or indirectly on the same receptor. It can be
competetive or non-competetive.
Physiological antagonism: Antagonist effects on a
physiological mechanism that is antagonist to the pathway
that agonist effects.
Pharmacokinetic antagonism: Interaction of antagonist on
absorption, distribution, metabolism, and elimination
(ADME) of agonist.
57
57
58
58
29
31. Quantifying antagonism
Characteristic patterns of antagonism are associated with
certain mechanisms of blockade of receptors. One is simple
competitive antagonism, whereby a drug that lacks intrinsic
efficacy but retains affinity competes with the agonist for the
binding site on the receptor. The characteristic pattern of such
antagonism is the concentration-dependent production of a
parallel shift to the right of the agonist dose-response curve
with no change in the maximal asymptotic response.
Competitive antagonism is surmountable by a sufficiently high
concentration of agonist.
The magnitude of the rightward shift of the curve depends on
the concentration of the antagonist and its affinity for the
receptor. The affinity of a competitive antagonist for its receptor
therefore can be determined according to its concentration-
dependent capacity to shift the concentration-response curve
for an agonist rightward, as analyzed by Schild (1957).
61
61 Goodman & Gilman Pharmacology, 11th edition
Reversible competitive antagonism I
62
62
31
32. Reversible competitive antagonism II
Dose Ratio (r):
The ratio=
agonist concentration (dose) required to produce a given
response (effect) in the presence of an antagonist
agonist concentration (dose) required to produce the same
response in the absence of an antagonist
Schild plot (regression): When logarithm of antagonist
concentration (logC) is plotted on X axis, and log(r-1) on Y axis,
all points are on the same line. The line meets X axis when dose
ratio is 2 (i.e. log(2-1)=0). The antagonist concentration at this
point is called KB.
KB: The antagonist concentration that makes dose ratio 2 (a
constant value).
63
63
64
64
32
33. Reversible competitive antagonism III
pA2= -logKB It determines the afinity of antagonist to a
given receptor.
The pA2 value is constant for a competetive antagonist
binding to the same receptor subtype on different tissues.
pA10= -logX10 (X10 is the antagonist concentration that
makes dose ratio 10).
At competitive antagonism: pA2 - pA10 = log(9) = 0.95
65
65
Noncompetitive antagonism I
An antagonist may dissociate so slowly from the receptor
as to be essentially irreversible in its action. Under these
circumstances, the maximal response to the agonist will be
depressed at some antagonist concentrations.
Operationally, this is referred to as noncompetitive
antagonism, although the molecular mechanism of action
really cannot be inferred unequivocally from the effect.
66
66 Goodman & Gilman Pharmacology, 11th edition
33
34. Noncompetitive antagonism II
Noncompetitive antagonism can be produced by another
type of drug, referred to as an allosteric antagonist. This
type of drug produces its effect by binding a site on the
receptor distinct from that of the primary agonist and
thereby changing the affinity of the receptor for the
agonist. In the case of an allosteric antagonist, the affinity
of the receptor for the agonist is decreased by the
antagonist.
In contrast, some allosteric effects could potentiate the
effects of agonists. The interaction of benzodiazepines
(anxiolytics) with the GABAA receptor to increase the
receptor's affinity for GABA is an example of allosteric
potentiation.
67
67 Goodman & Gilman Pharmacology, 11th edition
Noncompetitive antagonism III
68
68
34
35. Desensitization and tachyphylaxis
Continued stimulation of cells with agonists generally
results in a state of desensitization (also referred to as
adaptation, refractoriness, or down-regulation) such that
the effect that follows continued or subsequent exposure
to the same concentration of drug is diminished.
This phenomenon known as tachyphylaxis occurs rapidly
and is very important in therapeutic situations; an example
is attenuated response to the repeated use of β receptor
agonists as bronchodilators for the treatment of asthma.
69
69
Thank you
70
70
35